- Home
- NRXS vs MDXH Comparison
NRXS vs MDXH Comparison
Compare NRXS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NRXS | MDXH |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 68.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRXS | MDXH |
|---|---|---|
| Price | $7.89 | $0.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.00 | $7.67 |
| AVG Volume (30 Days) | 132.4K | ★ 199.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,569,282.00 | N/A |
| Revenue This Year | $172.91 | $30.78 |
| Revenue Next Year | $115.71 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.21 | $0.40 |
| 52 Week High | $9.33 | $5.33 |
Technical Indicators
Market Signals| Indicator | NRXS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 31.97 |
| Support Level | $6.69 | $0.51 |
| Resistance Level | $8.40 | $0.75 |
| Average True Range (ATR) | 0.52 | 0.04 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 94.18 | 2.51 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.